Citigroup Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $31
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Samantha Semenkow maintains a Buy rating on Catalyst Pharmaceuticals (NASDAQ:CPRX) and raises the price target from $27 to $31.
August 09, 2024 | 10:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup analyst Samantha Semenkow maintains a Buy rating on Catalyst Pharmaceuticals and raises the price target from $27 to $31.
The raised price target and maintained Buy rating from a reputable analyst at Citigroup is likely to positively influence investor sentiment and drive short-term price appreciation for Catalyst Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100